281 related articles for article (PubMed ID: 29200082)
1. Pneumonitis in Irradiated Lungs After Nivolumab: A Brief Communication and Review of the Literature.
Manapov F; Roengvoraphoj O; Dantes M; Marschner S; Li M; Eze C
J Immunother; 2018; 41(2):96-99. PubMed ID: 29200082
[TBL] [Abstract][Full Text] [Related]
2. Radiologic features of pneumonitis associated with nivolumab in non-small-cell lung cancer and malignant melanoma.
Baba T; Sakai F; Kato T; Kusumoto M; Kenmotsu H; Sugiura H; Tominaga J; Oikado K; Sata M; Endo M; Yanagawa N; Sasaki S; Iwasawa T; Saito Y; Fujiwara Y; Ohe Y; Yamazaki N; Sakamoto T; Koshiba T; Kuwano K
Future Oncol; 2019 Jun; 15(16):1911-1920. PubMed ID: 31020849
[No Abstract] [Full Text] [Related]
3. Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial.
Bozorgmehr F; Hommertgen A; Krisam J; Lasitschka F; Kuon J; Maenz M; Huber PE; König L; Kieser M; Debus J; Thomas M; Rieken S
BMC Cancer; 2019 Nov; 19(1):1074. PubMed ID: 31703637
[TBL] [Abstract][Full Text] [Related]
4. Recurrent Episodes of Nivolumab-Induced Pneumonitis after Nivolumab Discontinuation and the Time Course of Carcinoembryonic Antigen Levels: A Case of a 58-Year-Old Woman with Non-Small Cell Lung Cancer.
de Jong C; Peters BJM; Schramel FMNH
Chemotherapy; 2018; 63(5):272-277. PubMed ID: 30572331
[TBL] [Abstract][Full Text] [Related]
5. Nivolumab for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia: A multicenter, open-label single-arm phase II trial.
Fujimoto D; Yomota M; Sekine A; Morita M; Morimoto T; Hosomi Y; Ogura T; Tomioka H; Tomii K
Lung Cancer; 2019 Aug; 134():274-278. PubMed ID: 31182249
[TBL] [Abstract][Full Text] [Related]
6. A pilot trial of nivolumab treatment for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia.
Fujimoto D; Morimoto T; Ito J; Sato Y; Ito M; Teraoka S; Otsuka K; Nagata K; Nakagawa A; Tomii K
Lung Cancer; 2017 Sep; 111():1-5. PubMed ID: 28838377
[TBL] [Abstract][Full Text] [Related]
7. Nivolumab-induced organizing pneumonitis in a patient with lung sarcomatoid carcinoma.
Gounant V; Brosseau S; Naltet C; Opsomer MA; Antoine M; Danel C; Khalil A; Cadranel J; Zalcman G
Lung Cancer; 2016 Sep; 99():162-5. PubMed ID: 27565934
[TBL] [Abstract][Full Text] [Related]
8. Thoracic Imaging of Non-Small Cell Lung Cancer Treated With Anti-programmed Death Receptor-1 Therapy.
Hammer M; Bagley S; Aggarwal C; Bauml J; Nachiappan AC; Simone CB; Langer C; Katz SI
Curr Probl Diagn Radiol; 2019; 48(2):142-147. PubMed ID: 29573843
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study.
Fujimoto D; Yoshioka H; Kataoka Y; Morimoto T; Kim YH; Tomii K; Ishida T; Hirabayashi M; Hara S; Ishitoko M; Fukuda Y; Hwang MH; Sakai N; Fukui M; Nakaji H; Morita M; Mio T; Yasuda T; Sugita T; Hirai T
Lung Cancer; 2018 May; 119():14-20. PubMed ID: 29656747
[TBL] [Abstract][Full Text] [Related]
10. Organizing pneumonia after thoracic radiotherapy followed by anti-PD-1 antibody treatment for patients with lung cancer: Three case reports.
Sakaguchi M; Maebayashi T; Aizawa T; Ishibashi N; Okada M
Thorac Cancer; 2019 Jun; 10(6):1503-1507. PubMed ID: 31124295
[TBL] [Abstract][Full Text] [Related]
11. High incidence and early onset of nivolumab-induced pneumonitis: four case reports and literature review.
Koyama N; Iwase O; Nakashima E; Kishida K; Kondo T; Watanabe Y; Takahashi H; Umebayashi Y; Ogawa Y; Miura H
BMC Pulm Med; 2018 Jan; 18(1):23. PubMed ID: 29378571
[TBL] [Abstract][Full Text] [Related]
12. Clinical Experience of Immunotherapy Treatment: Efficacy and Toxicity Analysis of the Compassionate Use Program of Nivolumab in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer.
Krefting F; Basara N; Schütte W; Späth-Schwalbe E; Alt J; Thiel S; Kimmich M; Fischer JR; Kurz S; Griesinger F; Christoph DC
Oncol Res Treat; 2019; 42(5):243-255. PubMed ID: 30995666
[TBL] [Abstract][Full Text] [Related]
13. Hyperprogressive disease in patients with non-small cell lung cancer treated with nivolumab: A case series.
Kanazu M; Edahiro R; Krebe H; Nishida K; Ishijima M; Uenami T; Akazawa Y; Yano Y; Yamaguchi T; Mori M
Thorac Cancer; 2018 Dec; 9(12):1782-1787. PubMed ID: 30328672
[TBL] [Abstract][Full Text] [Related]
14. Organizing Pneumonia after Nivolumab Treatment in a Patient with Pathologically Proven Idiopathic Pulmonary Fibrosis.
Kashiwada T; Minegishi Y; Saito Y; Kato T; Atsumi K; Seike M; Kubota K; Terasaki Y; Gemma A
J Nippon Med Sch; 2019; 86(1):43-47. PubMed ID: 30918156
[TBL] [Abstract][Full Text] [Related]
15. Frequency and imaging features of abdominal immune-related adverse events in metastatic lung cancer patients treated with PD-1 inhibitor.
Alessandrino F; Sahu S; Nishino M; Adeni AE; Tirumani SH; Shinagare AB; Awad MM
Abdom Radiol (NY); 2019 May; 44(5):1917-1927. PubMed ID: 30790009
[TBL] [Abstract][Full Text] [Related]
16. Pre-existing interstitial lung disease is associated with onset of nivolumab-induced pneumonitis in patients with solid tumors: a retrospective analysis.
Yamaguchi T; Shimizu J; Hasegawa T; Horio Y; Inaba Y; Hanai N; Muro K; Hida T
BMC Cancer; 2021 Aug; 21(1):924. PubMed ID: 34399710
[TBL] [Abstract][Full Text] [Related]
17. Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: A retrospective analysis.
Yamaguchi T; Shimizu J; Hasegawa T; Horio Y; Inaba Y; Yatabe Y; Hida T
Lung Cancer; 2018 Nov; 125():212-217. PubMed ID: 30429022
[TBL] [Abstract][Full Text] [Related]
18. Granulation Tissue-induced Pseudo-relapse During Nivolumab Treatment in Advanced Non-small Cell Lung Cancer.
Ando C; Ichihara E; Kano H; Iwamoto Y; Hirabae A; Nakasuka T; Maeda Y; Kiura K
In Vivo; 2019; 33(6):2113-2115. PubMed ID: 31662545
[TBL] [Abstract][Full Text] [Related]
19. Severe pneumonitis refractory to steroids following anti-PD-1 immunotherapy.
Andruska N; Mahapatra L; Hebbard C; Patel P; Paul V
BMJ Case Rep; 2018 Oct; 2018():. PubMed ID: 30301729
[TBL] [Abstract][Full Text] [Related]
20. Unusual skin toxicity associated with sustained disease response induced by nivolumab in a patient with non-small cell lung cancer.
Galli G; Proto C; Cossa M; Valeri B; Sdao S; Signorelli D; Imbimbo M; de Braud F; Garassino MC; Lo Russo G
Tumori; 2019 Dec; 105(6):NP57-NP62. PubMed ID: 31456503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
